This study evaluated the efficacy and safety of docetaxel, cisplatin and 5-fluorouracil/leucovorin as neoadjuvant chemotherapy before surgery (NCT group; n = 29) compared with postoperative chemotherapy alone (non-NCT group; n = 26) in the treatment of Borrmann type IV gastric carcinoma. Primary tumour response rate, surgical parameters, incised-edge residue rate, lymphatic metastasis status and side-effects were evaluated. The overall response rate was 58.6% in the NCT group, which included three (10.3%) patients in complete remission and 14 (48.3%) patients in partial remission. The postoperative pathological complete response rate was 6.9% (two patients) in the NCT group. NCT was associated with a significant increase in the radical resection rate and a significant decrease in the rate of incised-edge residues, compared with postoperative chemotherapy alone. Side-effects due to NCT were minimal and resolved with appropriate treatment. There were no chemotherapy-related deaths in either group. In conclusion, docetaxel, cisplatin and 5-fluorouracil/leucovorin was an effective and well-tolerated NCT regimen for Borrmann type IV gastric cancer.
BorrmannR: Geschwulste Des Magens und Des Duodenums. In: Handbuch der Speziellen Pathologichen Anatomie und Histologic (HenkeFLubarschO, eds). Berlin: Springer, 1986; pp 812–1054 [in German].
2.
FurukawaHHiratsukaMIwanagaT: A rational technique for surgical operation on Borrmann type 4 gastric carcinoma: left upper abdominal evisceration plus Appleby's method. Br J Surg1988; 75: 116–119.
3.
ShinSHJungHChoiSH: Clinical significance of splenic hilar lymph node metastasis in proximal gastric cancer. Ann Surg Oncol2009; 16: 1304–1309.
4.
ZhaoXHuangKZhuZ: Correlation between expression of leptin and clinicopathological features and prognosis in patients with gastric cancer. J Gastroenterol Hepatol2007; 22: 1317–1321.
5.
KimDYKimHRKimYJ: Clinicopathological features of patients with Borrmann type IV gastric carcinoma. ANZ J Surg2002; 72: 739–742.
6.
KwonSJLeeGJ: Clinicopathologic characteristics of Borrmann type 4 gastric cancer. J Korean Surg Soc2003; 64: 127–133.
7.
KangMHKimSNKimNK: Clinical outcomes and prognostic factors of metastatic gastric carcinoma patients who experience gastrointestinal perforation during palliative chemotherapy. Ann Surg Oncol2010; 17: 3163–3172.
8.
ParkJCLeeYCKimJH: Clinicopathological aspects and prognostic value with respect to age: an analysis of 3,362 consecutive gastric cancer patients. J Surg Oncol2009; 99: 395–401.
9.
OhSYLeeSJLeeJ: Gastric leptomeningeal carcinomatosis: multi-center retrospective analysis of 54 cases. World J Gastroenterol2009; 15: 5086–5090.
10.
LiuYYoshimuraKYamaguchiN: Causation of Borrmann type 4 gastric cancer: heritable factors or environmental factors?Gastric Cancer2003; 6: 17–23.
11.
DickenBJBigamDLCassC: Gastric adenocarcinoma: review and considerations for future directions. Ann Surg2005; 241: 27–39.
12.
AhnHSLeeHJYooMW: Changes in clinicopathological features and survival after gastrectomy for gastric cancer over a 20-year period. Br J Surg2011; 98: 255–260.
13.
TanigawaNAmayaHMatsumuraM: Association between tumor angiogenesis and Borrmann type 4 carcinomas of the stomach. Oncology1998; 55: 461–467.
14.
TakedaJHashimotoKKoufujiK: A retrospective study of resected gastric cancers. Kurume Med J1992; 39: 141–145.
15.
ParkJCLeeYCKimJH: Clinicopathological features and prognostic factors of proximal gastric carcinoma in a population with high Helicobacter pylori prevalence: A single-center, large-volume study in Korea. Ann Surg Oncol2010; 17: 829–837.
16.
CabralJA FloresVojvodicIOrtegaD: Factors associated with postoperative mortality following gastric adenocarcinoma surgery at the Edgardo Rebagliati Martins Hospital. Rev Gastroenterol Peru2004; 24: 212–222 [in Spanish, English abstract].
17.
YonemuraYBandouEKinoshitaK: Effective therapy for peritoneal dissemination in gastric cancer. Surg Oncol Clin N Am2003; 12: 635–648.
18.
MlkvýP: Multimodal therapy of gastric cancer. Dig Dis2010; 28: 615–618.
19.
HalimAWahbaH: Second-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC. Med Oncol2011; 25: 25–29.
20.
SuhDHKimJWKimK: Major clinical research advances in gynecologic cancer in 2010. J Gynecol Oncol2010; 21: 209–218.
21.
MillerABHoogstratenBStaquetM: Reporting results of cancer treatment. Cancer1981; 47: 207–214.
22.
EisenhauerEATherassePBogaertsJ: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer2009; 45: 228–247.
23.
YokotaTTeshimaSSaitoT: Borrmann's type IV gastric cancer: clinicopathologic analysis. Can J Surg1999; 42: 371–376.
24.
AllumWHGriffinSMWatsonA: Guidelines for the management of oesophageal and gastric cancer. Gut2002; 50 (suppl 5): v1–v23.
25.
KonishiTNoieTYoshidaJ: Treatment of peritoneal dissemination of gastric cancer with sequential methotrexate and 5-fluorouracil. Gastric Cancer1999; 2: 52–56.
WilkeHPreusserPFinkU: Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: A phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol1989; 7: 1318–1326.
28.
GrazianoFCatalanoVBaldelliAM: A phase II study of weekly docetaxel as salvage chemothrapy for advanced gastric cancer. Ann Oncol2000; 11: 1263–1266.
29.
HoneckerFKollmannsbergerCQuietzschD: Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anticancer Drugs2002; 13: 497–503.
30.
KollmannsbergerCQuietzschDHaagC: A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer2000; 83: 458–462.
